AstraZeneca PLC (AZNCF)
| Previous Close | 136.00 |
| Open | 139.04 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 139.04 - 139.04 |
| 52 Week Range | 104.50 - 143.90 |
| Volume | |
| Avg. Volume | 3,057 |
| Market Cap | 215.447B |
| Beta (5Y Monthly) | 0.21 |
| PE Ratio (TTM) | 108.62 |
| EPS (TTM) | 1.28 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.80 (2.06%) |
| Ex-Dividend Date | Aug 11, 2022 |
| 1y Target Est | N/A |
- Business Wire
Camizestrant Significantly Delayed Disease Progression in Advanced ER-Positive Breast Cancer, Adding at Least 3.5 Months Benefit Versus FASLODEX® (fulvestrant)
WILMINGTON, Del., December 08, 2022--Detailed results from the SERENA-2 Phase II trial showed AstraZeneca’s next-generation oral selective estrogen receptor degrader (ngSERD) camizestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) at both 75mg and 150mg dose levels versus FASLODEX® (fulvestrant) 500mg in post-menopausal patients with estrogen receptor (ER)-positive locally advanced or metastatic breast cancer, previously trea
- Business Wire
Capivasertib Plus FASLODEX® (fulvestrant) Reduced the Risk of Disease Progression or Death by 40% Versus FASLODEX in Advanced HR-Positive Breast Cancer
WILMINGTON, Del., December 08, 2022--Detailed results from the CAPItello-291 Phase III trial showed AstraZeneca’s capivasertib in combination with FASLODEX® (fulvestrant) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus placebo plus FASLODEX in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-low or negative, locally advanced or metastatic breast cancer, following recurrence or pr
- Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Achieved Statistically Significant Overall Survival, Reducing the Risk of Death by 36% Vs. Trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Breast cancer in DESTINY-Breast03
WILMINGTON, Del., December 07, 2022--Updated results from the DESTINY-Breast03 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to trastuzumab emtansine (T-DM1) in patients with HER2-positive unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane. These results and primary results from the DESTINY-Breast02 Phase III trial wi
